Pluvicto (lutetium Lu 177 vipivotide tetraxetan) is a prescription drug that’s used to treat prostate cancer in certain situations. Pluvicto comes as a solution for injection or infusion. Pluvicto is ...

The FDA has approved a new formulation of an F 18 prostate-specific membrane antigen imaging agent for men with prostate ...

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.

New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines the diagnostic performance of PYLARIFY ® (piflufolastat F 18) with the potential for larger ...

“This is a rare opportunity for me personally, this is my only hope to extend my life by any real period at all." The post Man first in Europe to trial new antibody drug for prostate cancer appeared ...

Manufacturing optimization is projected to expand batch output by ~50%, improving supply reliability and supporting higher-throughput PSMA PET imaging services. Increased radioactivity extends shelf ...

Immunotherapies use the power of your immune system to fight your cancer. Vaccines are one form of immunotherapy. Sipuleucel-T is a vaccine used for advanced, metastatic prostate cancer if: It no ...